GlassScriptPhysician profile
Margaret Biggins
NPI 1225580400
$1,598.72
in general payments reported to CMS, 2019-2025
10 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $72.19 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $510.55 | 2025 | Fasenra, Tezspire, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $398.45 | 2024-2025 | Glassia |
| Jazz Pharmaceuticals INC. | $326.84 | 2025 | |
| Axsome Therapeutics, INC. | $95.41 | 2025 | Sunosi |
| Lilly USA, LLC | $85.65 | 2025 | Zepbound |
| Verona Pharma, INC. | $60.36 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $43.19 | 2025 | |
| Grifols USA, LLC | $30.91 | 2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $29.57 | 2024 | Zemaira |
| Electromed, INC. | $17.79 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Biggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.